|
Jeffrey M. Jonas, M.D. joined Isis as Executive Vice President in February 2007. Dr. Jonas leads Clinical Development, Preclinical Development, Regulatory Affairs, and Quality Assurance and Compliance at Isis. He is broadly responsible for the entire pipeline, both partnered and unpartnered, and will contribute to portfolio management.
Prior to joining Isis Pharmaceuticals, Dr. Jonas was Chief Medical Officer and Executive Vice President at Forest Laboratories, Inc., responsible for Clinical Development, Medical Affairs, Pharmacovigilence, Regulatory Affairs, Health Economics, and External Scientific Affairs. Dr. Jonas joined Forest in 2003 as VP, Central Nervous System Area. In 2005, he was promoted to Senior VP, Clinical Development. In 2006, he was promoted to his current position. Dr. Jonas’ initial experience in the pharmaceutical industry began in 1991 at Upjohn Laboratories initially as Director of Psychopharmacology and after several promotions ultimately as Chief Medical Officer and VP, Clinical Development. He has been responsible for numerous successful INDs and NDAs for drugs in a wide range of therapeutic classes.
In addition, Dr. Jonas has been a successful entrepreneur. He founded and led AVAX Technologies, a leader in autologous cell therapy and individualized therapy. During his tenure, he led AVAX through several successful financings, including an initial public offering in 1997. In 2001, he founded SCEPTOR Industries, a biotechnology company involved in biodefense surveillance.
Dr. Jonas has published more than 70 scientific papers and chapters and has received a number of awards. Dr. Jonas received his M.D. from Harvard Medical School in 1979, completed a residency in psychiatry at Harvard following which he was Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.
| 